ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CLA1352 |
|
1105038-73-0 |
Abituzumab (Anti-Integrin aV / ITGAV / CD51) 95+% |
— | |
CLA1265 |
|
1044758-60-2 |
Etrolizumab (Anti-Integrin α4β7) (ITGA4 & ITGB7) 95+% |
— | |
CLA1226 |
|
339086-79-2 |
Rovelizumab 95+% |
— | |
CLA1211 |
|
211323-03-4 |
Erlizumab (Anti-Integrin b2 / ITGB2 / CD18) 95+% |
— | |
CLA1196 |
|
558480-40-3 |
Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) 95+% |
— | |
CLA1185 |
|
892553-42-3 |
Etaracizumab 95+% |
— | |
CLA1118 |
|
143653-53-6 |
Abciximab 95+% |
— | |
CLA1108 |
|
159445-64-4 |
Odulimomab 95+% |
— | |
CLA1097 |
|
142864-19-5 |
Enlimomab 95+% |
— | |
CLA1084 |
|
339086-80-5 |
Tadocizumab 95+% |
— | |
CLA1062 |
|
214745-43-4 |
Anti-Human CD11a Monoclonal Antibody(Efalizumab) 95+% |
— | |
CLA1024 |
|
189261-10-7 |
Natalizumab 98+% |
— | |
CLA1011 |
|
943609-66-3 |
Vedolizumab 98+% |
— | |